NCT04817371

Brief Summary

In the context of the actual pandemia of the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which requires a better diagnostic strategy for the management of patients. The study of volatile organic compounds (VOC) detected in exhaled air or in sweat, is an innovative research area for respiratory diseases. The analysis of VOC can be done either by the technique of the mass spectrometry which allows the identification of each VOC in the exhaled air or by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the VOC without identifying them. The VOC have shown their interest in some situations, such as diagnostic or prognostic tool in patients followed for thoracic tumorous pathology or bronchial or pulmonary vascular diseases. Moreover, it has recently been shown that properly trained dogs would be able to detect an olfactory signature of SARS-CoV-2 infection with a specificity greater than 90%; this olfactory signature corresponds to VOCs detectable by the flair of dogs (Nosaïs-Covid19 study). Validation of the diagnostic value of VOC analyzes by non-invasive and rapid methods (electronic nose analysis or mass spectrometry; detection by the scent of dogs) for the rapid detection and early diagnosis of a SARS-CoV-2 infection warrants the performance of this clinical study.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
192

participants targeted

Target at P50-P75 for not_applicable covid19

Timeline
Completed

Started Mar 2021

Typical duration for not_applicable covid19

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2021

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

March 15, 2021

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 26, 2021

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2022

Completed
Last Updated

August 3, 2022

Status Verified

August 1, 2022

Enrollment Period

1.5 years

First QC Date

March 15, 2021

Last Update Submit

August 2, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • The first co-objective of this experimental study is to determine if VOCs analyzed by electronic noses are of interest for the diagnosis of an infection by SARS-CoV-2 (COVID-19) infection.

    Identification of VOC profiles specific to the SARS-CoV-2 (VOC analysis by electronic noses) on exhalates collected under resting breathing conditions between patients with symptoms suggestive of COVID-19 and SARS-CoV-2 infection confirmed by RT-PCR, those whose infection is ruled out on the basis of the negativity RT-PCR and clinical/radiological data (non-COVID control patients), and those with another symptomatic respiratory viral infection confirmed by positive PCR for viruses other than SARS-CoV-2 other than SARS-CoV-2.

    1 day

  • The second co-objective of this experimental study is to determine if VOCs analyzed by mass spectrometry is of interest for the diagnosis of an infection by SARS-CoV-2 (COVID-19) infection.

    Identification of VOC profiles specific to the SARS-CoV-2 (VOC analysis by mass spectrometry) on exhalates collected under resting breathing conditions between patients with symptoms suggestive of COVID and SARS-CoV-2 infection confirmed by RT-PCR, those whose infection is ruled out on the basis of the negativity RT-PCR and clinical/radiological data (non-COVID control patients), and those with another symptomatic respiratory viral infection confirmed by positive PCR for viruses other than SARS-CoV-2 other than SARS-CoV-2.

    1 day

Secondary Outcomes (2)

  • Identify the nature of VOCs associated with infection by SARS-CoV-2 by mass spectrometry in exhaled air and in sweat

    1 day

  • Assessment of the specificity and sensitivity of canine olfactory detection of COVs associated with infection by SARS-CoV-2 (COVID-19)

    1 day

Study Arms (4)

Symptomatic patients with positive PCR

OTHER

Patients with symptoms of COVID-19 and whose PCR result is positive

Device: Volatile Organic Compounds analysis (e-noses)Other: Canine odor detection of Volatile Organic CompoundsDevice: Volatile Organic Compounds analysis (mass spectrometry)Device: Volatile Organic Compounds analysis in sweat (mass spectrometry)

Symptomatic patients with positive PCR for other respiratory virus

OTHER

Patients with symptomatic respiratory disease of infectious origin with negative RT-PCR for SARS-CoV-2 and positive RT-PCR for other respiratory viruses

Device: Volatile Organic Compounds analysis (e-noses)Other: Canine odor detection of Volatile Organic CompoundsDevice: Volatile Organic Compounds analysis (mass spectrometry)Device: Volatile Organic Compounds analysis in sweat (mass spectrometry)

Asymptomatic patients or healthy volunteers

OTHER

Patients or healthy volunteers with negative RT-PCR and negative serology

Device: Volatile Organic Compounds analysis (e-noses)Other: Canine odor detection of Volatile Organic CompoundsDevice: Volatile Organic Compounds analysis (mass spectrometry)Device: Volatile Organic Compounds analysis in sweat (mass spectrometry)

Volunteers or patients vaccinated against COVID-19

OTHER

Volunteers or patients vaccinated against COVID-19 (complete vaccination scheme)

Device: Volatile Organic Compounds analysis (e-noses)Other: Canine odor detection of Volatile Organic CompoundsDevice: Volatile Organic Compounds analysis (mass spectrometry)Device: Volatile Organic Compounds analysis in sweat (mass spectrometry)

Interventions

VOC analysis in exhaled air with e-noses.

Asymptomatic patients or healthy volunteersSymptomatic patients with positive PCRSymptomatic patients with positive PCR for other respiratory virusVolunteers or patients vaccinated against COVID-19

VOC analysis in sweat by trained dogs.

Asymptomatic patients or healthy volunteersSymptomatic patients with positive PCRSymptomatic patients with positive PCR for other respiratory virusVolunteers or patients vaccinated against COVID-19

VOC analysis in exhaled air with mass spectrometry.

Asymptomatic patients or healthy volunteersSymptomatic patients with positive PCRSymptomatic patients with positive PCR for other respiratory virusVolunteers or patients vaccinated against COVID-19

VOC analysis in sweat with mass spectrometry.

Asymptomatic patients or healthy volunteersSymptomatic patients with positive PCRSymptomatic patients with positive PCR for other respiratory virusVolunteers or patients vaccinated against COVID-19

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject included in the Foch Hospital :
  • Patients managed at the Foch Hospital with RT-PCR screening for SARS-CoV-2 infection
  • Healthy volunteers among the hospital staff, asymptomatic, for whom an RT-PCR SARS-CoV-2 is indicated or recommended.
  • Healthy hospital volunteers vaccinated against COVID (full vaccination schedule completed)
  • At least 18 years of age;
  • Fluency in the French language;
  • Have signed a consent form;
  • Be affiliated with a health insurance plan.

You may not qualify if:

  • Pregnant woman
  • Patient deprived of liberty by judicial or administrative decision

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Foch hospital

Suresnes, 92151, France

RECRUITING

MeSH Terms

Conditions

COVID-19

Interventions

Mass Spectrometry

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Chemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Philippe Devillier, PhD

    Hopital Foch

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Philippe Devillier, PhD

CONTACT

Elisabeth Hulier-Ammar, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 15, 2021

First Posted

March 26, 2021

Study Start

March 1, 2021

Primary Completion

September 1, 2022

Study Completion

September 1, 2022

Last Updated

August 3, 2022

Record last verified: 2022-08

Locations